Search

Your search keyword '"Wijsman R"' showing total 271 results
Start Over Author "Wijsman R"
271 results on '"Wijsman R"'

2. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study

Author

Amir, M.I., van Berkum, H., Bertens, H., Bindels, M., Bongers, E.M., Boshuizen, R.C., de Brake-de Jong, K., Braun, J., van den Broek, F.J.C., Bussink, J., Canisius, S., Damhuis, R.A.M., Deelen, M., Deroose, J.P., Dickhoff, C., Dielwart, M.F.H., van Diessen, J.N.A., Dubbelman-Siems, M., van Elst, K., Ghamati, M., Grimme, F.A.B., de Groot, M.A., Halfwerk, F.R., Hartemink, K.J., Hellebrekers, P., Hendriks, L.E.L., Hendriksa, E.R., van Heukelem, S., ten Heuvel, A., Hugen, N., Hutteman, M., Hüyük, M., IJgosse, W.M., de Jaeger, K., de Jong, E.M., van Kampen, D., de Keersmaecker, S., Klomp, H.M., Kouwenhoven, E.A., Krouwels, F.H., Lammers, E., Lastdrager, W.B., van der Leest, K., Liesker, K.R., de Loos, E.R., De Lorenzo, A., Maat, A.P.W.M., Maessen, J.G., Mali, R., Marquenie, N., Marres, G.M.H., Martina, B.G., Masselink, I., Meijer, R.C.A., Mens, D.M., von Meyenfeldt, E.M., Michel, S., van Middendorp, L.B., Moes, J.R., Moons-Pasic, A., Morsink, L., van Nes, J.G.H., van Nistelrooy, M., van der Noort, V., Nuyttens, J.J.M.E., Oosterhuis, J.W.A., Oosthoek, L.W.J., Osté, E., Overhof-Wedick, C., Palamba, H.W., Paulus, G.F., van Putten, J.W.G., van Putten, S.E., Rijna, H., Rikers, C., de Ruiter, J.C., de Ruysscher, D.K., Schiefer, M., Schweitzer, D., Smakman, N., Smit, E.F., Smit, W.G.J.M., Spaans, L.N., Speekenbrink, R.G.H., Stellingwerf, M., Steward, A.J., Susa, D., van Thiel, E., Thönissen, N.M., Veen, E.J., Veenhof, A.A.F.A., van Velthoven-Hoogers, A., Verbogt, N.P.A., Verbruggen, L., Verhagen, A.F.T.M., Verhoeff, J.J.C., van der Voort van Zyp, N.C.M.G., van de Wauwer, C., de Wee, E.M., van der Wekken, A.J., Wener, R.R., Wijsman, R., van den Wildenberg, F.J.H., van der Woude, L., Yang, Z.L., de Ruiter, Julianne Cynthia, van der Noort, Vincent, van Diessen, Judi Nani Annet, Smit, Egbert Frederik, Damhuis, Ronald Alphons Maria, and Hartemink, Koen Johan

Published
2024
Full Text
View/download PDF

4. Thoracale oncologie

Author

van Spil, J. A., Olijve, A., Hiddinga, B. I., Van De Wauwer, C., Wijsman, R., van Spil, J.A., editor, van Muilekom, H.A.M., editor, Folsche, M., editor, and Schreuder-Cats, H.A., editor

Published
2021
Full Text
View/download PDF

5. MO-0470 IMPT reduces esophageal and pulmonary toxicity compared to VMAT in stage II-IV NSCLC patients

Author

Hessels, A., primary, Stoffers, R., additional, Niezink, A., additional, Chouvalova, O., additional, Ubbels, F., additional, van der Leest, A., additional, Woltman - van Iersel, M., additional, Deseyne, P., additional, Elzinga, H., additional, Haan - Stijntjes, E., additional, Korevaar, E., additional, Pisciotta, P., additional, Langendijk, H., additional, and Wijsman, R., additional

Published
2023
Full Text
View/download PDF

8. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.

Author

Dieleman, E., Woude, L. van der, Os, R. van, Bockel, L. van, Coremans, I., Es, C. van, Jaeger, K. de, Knol, H.P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Voort van Zyp, N. van der, Wel, A. van der, Wijsman, R., Dielwart, M., Wiegman, E., Damhuis, R., Belderbos, J., Dieleman, E., Woude, L. van der, Os, R. van, Bockel, L. van, Coremans, I., Es, C. van, Jaeger, K. de, Knol, H.P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Voort van Zyp, N. van der, Wel, A. van der, Wijsman, R., Dielwart, M., Wiegman, E., Damhuis, R., and Belderbos, J.

Abstract

Item does not contain fulltext, INTRODUCTION: Chemoradiotherapy (CRT) is the standard of care in inoperable non-small-cell lung cancer (NSCLC) patients, favoring concurrent (cCRT) over sequential CRT (seqCRT), with adjuvant immunotherapy in responders. Elderly and frail NSCLC patients have generally been excluded from trials in the past. In elderly patients however, the higher treatment related morbidity of cCRT, may outweigh the possible lower tumor control of seqCRT. For elderly patients with locally advanced NSCLC real-world data is essential to be able to balance treatment toxicity and treatment outcome. The aim of this study is to analyze acute toxicity and 3-month mortality of curative chemoradiation (CRT) in patients with stage III NSCLC and to analyze whether cCRT for elderly stage III NSCLC patients is safe. METHODS: The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R) is a national lung cancer audit that started in 2013 for patients treated with curative intent radiotherapy. All Dutch patients treated for stage III NSCLC between 2015 and 2018 with seqCRT or cCRT for (primary or recurrent) stage III lung cancer are included in this population-based study. Information was collected on patient, tumor- and treatment characteristics and the incidence and severity of acute non-hematological toxicity (CTCAE-4 version 4.03) and mortality within 3 months after the end of radiotherapy. To evaluate the association between prognostic factors and outcome (acute toxicity and mortality within 3 months), an univariable and multivariable analysis was performed. The definition of cCRT was:radiotherapy started within 30 days after the start of chemotherapy. RESULTS: Out of all 20 Dutch departments of radiation oncology, 19 centers participated in the registry. A total of 2942 NSCLC stage III patients were treated with CRT. Of these 67.2% (n = 1977) were treated with cCRT (median age 66 years) and 32.8% (n = 965) were treated with seqCRT (median age 69 years). Good performance status (WHO 0-1) was scored in 88

Published
2023

11. 957P Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on toxicity and immune therapy

Author

Cortiula, F., primary, Hendriks, L., additional, Wijsman, R., additional, Debakker, S., additional, Steens, M., additional, Peeters, S.T., additional, Michelotti, A., additional, Sijtsema, N.M., additional, Urban, S., additional, Niezink, A., additional, Dursun, S., additional, Bootsma, G., additional, Canters, R., additional, Tohidinezhad, F., additional, Fasola, G., additional, Rinaldi, I., additional, Taasti, V., additional, Houben, R., additional, and De Ruysscher, D., additional

Published
2022
Full Text
View/download PDF

13. Introduction of IMPT for NSCLC patients: the learning curve in practice

Author

Wijsman, R., Chouvalova, O., Klinker, P., Niezink, A., van der Leest, A., Ubbels, F., Woltman-van Iersel, M., Both, S., Korevaar, E., Langendijk, J., Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Damage and Repair in Cancer Development and Cancer Treatment (DARE)

Published
2022

24. DLCA-R: Variation in elderly stage III NSCLC treated with definitive chemoradiation

Author

Dieleman, E., van der Woude, L., Vonk, E., van Bockel, L., Coremans, I., van Es, C., de Jaeger, K., Knol, H. P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Ubbels, F., van Zyp, N. van der Voort, van der Wel, A., Wijsman, R., Dielwart, M., Wiegman, E., and Belderbos, J.

Published
2021

45. PO-1162 DLCA-R: Variation in elderly stage III NSCLC treated with definitive chemoradiation.

Author

Dieleman, E., primary, van der Woude, L., additional, Vonk, E., additional, van Bockel, L., additional, Coremans, I., additional, van Es, C., additional, de Jaeger, K., additional, Knol, H.P., additional, Kolff, W., additional, Koppe, F., additional, Pomp, J., additional, Reymen, B., additional, Schinagl, D., additional, Spoelstra, F., additional, Tissing-Tan, C., additional, Ubbels, F., additional, van der Voort van Zyp, N., additional, van der Wel, A., additional, Wijsman, R., additional, Dielwart, M., additional, Wiegman, E., additional, and Belderbos, J., additional

Published
2021
Full Text
View/download PDF

46. Dutch Lung Cancer Audit-Radiotherapy: Real-World Data on Stage III Non-Small Cell Lung Cancer Treated With Radiotherapy Only

Author

Van Bockel, L., Van der Woude, L., De Jaeger, K., Coremans, I., Damhuis, R., Van Es, C., Van der Geest, A., Van Kampen, D., Knol, H. P., Kolff, W., Koppe, F., Pomp, J., Reymen, B., Schinagl, D., Spoelstra, F., Tissing-Tan, C., Vonk, E., Van der Voort-Van Zijp, N., Van der Wel, A., Wijsman, R., Wiegman, E., and Belderbos, J.

Subjects
radical radiotherapy, DLCA-R, Real-world data
Published
2021

50. Investigation of inter-fraction target motion variations in the context of pencil beam scanned proton therapy in non-small cell lung cancer patients

Author

Den Otter, L. A., Anakotta, R. M., Weessies, M., Roos, C. T. G., Sijtsema, N. M., Muijs, C. T., Dieters, M., Wijsman, R., Troost, E. G. C., Richter, C., Meijers, A., Langendijk, J. A., Both, S., and Knopf, A.-C.

Subjects
lung cancer, spencil beam scanning proton therapy, moving target, free breathing, inter-fractional motion monitoring
Abstract

Purpose: For locally advanced-stage non-small cell lung cancer (NSCLC), inter-fraction target motion variations during the whole time span of a fractionated treatment course are assessed in a large and representative patient cohort. The primary objective is to develop a suitable motion monitoring strategy for pencil beam scanning proton therapy (PBS-PT) treatments of NSCLC patients during free breathing. Methods: Weekly 4D computed tomography (4DCT; 41 patients) and daily 4D cone beam computed tomography (4DCBCT; 10 of 41 patients) scans were analyzed for a fully fractionated treatment course. Gross tumor volumes (GTVs) were contoured and the 3D displacement vectors of the centroid positions were compared for all scans. Furthermore, motion amplitude variations in different lung segments were statistically analyzed. The dosimetric impact of target motion variations and target motion assessment was investigated in exemplary patient cases. Results: The median observed centroid motion was 3.4 mm (range: 0.2–12.4 mm) with an average variation of 2.2 mm (range: 0.1–8.8 mm). Ten of 32 patients (31.3%) with an initial motion 2 mm, 4DCBCT should be considered for motion monitoring due to substantial motion variations observed. ©2020 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results